ADR Biomedical Holdings Inc.
ADR Biomedical Holdings Inc. Disclosure: Notice of Commencement of Clinical Trial for Severe Limb Ischemia Treatment
A subsidiary resolved to commence a clinical trial of an ADRC-based therapy derived from adipose tissue targeting severe limb ischemia. Consultation on the clinical trial protocol with the PMDA has been completed, and the joint research agreement with Nagoya University will continue. The company aims for practical application and insurance coverage in the future, but the impact on financial results is currently undetermined and under review.
Key Figures
- Resolution to commence clinical trial (date TBD)
- Joint research agreement: Concluded with Nagoya University (previously reported)
- PMDA clinical trial protocol consultation completed (previously reported)
AI要約
Overview of Clinical Trial Initiation and Research Framework
The subsidiary ADR Therapeutics Inc. resolved at its board meeting to commence a clinical trial of a therapy using adipose-derived regenerative cells (ADRCs) targeting severe limb ischemia. It emphasizes verification under the joint research agreement with Nagoya University and that consultation with the PMDA on the clinical trial protocol has been completed.
Future Impact on Financial Results and Schedule
The direct impact of commencing the clinical trial on financial results is currently under review, and any matters requiring disclosure will be announced promptly. The clinical trial is at a verification stage aimed at practical application and insurance coverage, and no specific figures have been disclosed at this time.
ADR Biomedical Holdings Inc.
Company overview · Stock price · Financial data · All IR
